U.S. Genotyping Market Size & Outlook, 2023-2030
U.S. genotyping market, 2018-2030 (US$M)
Related Markets
U.S. genotyping market highlights
- The U.S. genotyping market generated a revenue of USD 6,421.7 million in 2023 and is expected to reach USD 16,362.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 14.3% from 2024 to 2030.
- In terms of segment, reagents & kits was the largest revenue generating product in 2023.
- Reagents & kits is the most lucrative product segment registering the fastest growth during the forecast period.
Genotyping market data book summary
| Market revenue in 2023 | USD 6,421.7 million |
| Market revenue in 2030 | USD 16,362.9 million |
| Growth rate | 14.3% (CAGR from 2023 to 2030) |
| Largest segment | Reagents & kits |
| Fastest growing segment | Reagents & kits |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Reagents & kits, Services |
| Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Roche, Fluidigm Corporation, Danaher Corp, Agilent Technologies, Eurofins Scientific SE, GE HealthCare Technologies Inc Common Stock, Bio-Rad Laboratories Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.8% of the global genotyping market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. genotyping market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,778.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genotyping Market Scope
Genotyping Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. genotyping market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genotyping market will help companies and investors design strategic landscapes.
Reagents & kits was the largest segment with a revenue share of 61.15% in 2023. Horizon Databook has segmented the U.S. genotyping market based on instruments, reagents & kits, services covering the revenue growth of each sub-segment from 2018 to 2030.
Genotyping is widely used in the U.S. for a variety of purposes, such as drug discovery, personalized medicine, diagnostic research, and agriculture. In 2018, in the U.S., a new landmark in dairy genetics was achieved, as 2 million individual animal genotypes were recorded in dairy database.
Furthermore, strategic initiatives undertaken by local players are anticipated to contribute to market growth. For instance, in February 2021, VG acquisition Corp. merged with 23andMe, a U.S.-based genetics and research company actively working with direct-to-consumer genotypic solutions.
This merger would provide capital funds for their genetic consumer health business. These factors are expected to propel market growth. Local presence of key market players in the country is anticipated to increase penetration of genotyping products in the market.
Reasons to subscribe to U.S. genotyping market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. genotyping market databook
-
Our clientele includes a mix of genotyping market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. genotyping market , including forecasts for subscribers. This country databook contains high-level insights into U.S. genotyping market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. genotyping market size, by product, 2018-2030 (US$M)
U.S. Genotyping Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
